SpringerLink
Log in

Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

The adjusted global antiphospholipid syndrome score (aGAPSS) is a recently developed thrombotic risk assessment score that considers the antiphospholipid antibody (aPL) profile and conventional cardiovascular risk factors. In this retrospective study, we aimed to evaluate the validity of the aGAPSS in predicting clinical manifestations (criteria and extra-criteria) of antiphospholipid syndrome (APS) in a single centre cohort of patients. Ninety-eight patients with APS ± systemic lupus erythematosus (SLE) were classified according to clinical manifestations as vascular thrombosis (VT), pregnancy morbidity (PM) or both (VT + PM). The aGAPSS was calculated for each patient as previously defined. Mean aGAPSS of the cohort was calculated as 10.2 ± 3.8. Significantly higher aGAPSS values were seen in VT (n = 58) and VT + PM (n = 29) groups when compared to PM (n = 11) group (10.6 ± 3.7 vs 7.4 ± 2.9, P = 0.005; 10.7 ± 4 vs 7.4 ± 2.9, P = 0.008, respectively), mainly due to lower frequencies of cardiovascular risk factors in PM. Higher aGAPPS values were also associated with recurrent thrombosis (11.6 ± 3.7 vs 9.9 ± 3.6, P = 0.04). Regarding extra-criteria manifestations, patients with livedo reticularis (n = 11) and APS nephropathy (n = 9) had significantly higher aGAPSS values (12.9 ± 3.4 vs 9.9 ± 3.7, P = 0.02; 12.4 ± 2.9 vs 10 ± 3.8, P = 0.04, respectively). The computed AUC demonstrated that aGAPSS values ≥10 had the best diagnostic accuracy for thrombosis. Our results suggest that patients with higher aGAPSS values are at higher risk for develo** vascular thrombosis (either first event or recurrence) and extra-criteria manifestations, especially livedo reticularis and APS nephropathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.x

    Article  CAS  PubMed  Google Scholar 

  2. Petri M, Orbai AM, Alarcon GS et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686. https://doi.org/10.1002/art.34473

    Article  PubMed  PubMed Central  Google Scholar 

  3. Willis R, Pierangeli SS (2011) Pathophysiology of the antiphospholipid antibody syndrome. Auto Immun Highlights 2(2):35–52. https://doi.org/10.1007/s13317-011-0017-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827–1832. https://doi.org/10.1182/blood-2002-02-0441

    Article  CAS  PubMed  Google Scholar 

  5. Ruffatti A, Del Ross T, Ciprian M et al (2011) Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 70(6):1083–1086. https://doi.org/10.1136/ard.2010.142042

    Article  PubMed  Google Scholar 

  6. Reynaud Q, Lega J-C, Mismetti P, Chapelle C, Wahl D, Cathébras P, Laporte S (2014) Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 13:595–608. https://doi.org/10.1016/j.autrev.2013.11.004

    Article  CAS  PubMed  Google Scholar 

  7. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S (2005) Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 93(6):1147–1152. https://doi.org/10.1160/TH04-12-0839

    Article  CAS  PubMed  Google Scholar 

  8. Pericleous C, Rahman A (2014) Domain I: the hidden face of antiphospholipid syndrome. Lupus 23(12):1320–1323. https://doi.org/10.1177/0961203314540354

    Article  CAS  PubMed  Google Scholar 

  9. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML (2014) Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 111(2):354–364. https://doi.org/10.1160/TH13-06-0509

    Article  CAS  PubMed  Google Scholar 

  10. Cervera R, Serrano R, Pons-Estel GJ, on behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies) et al (2015) Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74:1011–1018. https://doi.org/10.1136/annrheumdis-2013-204838

    Article  CAS  PubMed  Google Scholar 

  11. Artim-Esen B, Çene E, Şahinkaya Y, Ertan S, Pehlivan Ö, Kamali S, Gül A, Öcal L, Aral O, Inanç M (2014) Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol 41(7):1304–1310. https://doi.org/10.3899/jrheum.130984

    Article  PubMed  Google Scholar 

  12. Miller CC, Reardon MJ, Safi HJ (2001) Risk stratification: a practical guide for clinicians. Cambridge University Press, Cambridge

    Book  Google Scholar 

  13. Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K, Horita T, Yasuda S, Koike T (2012) Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64:504–512. https://doi.org/10.1002/art.33340

    Article  CAS  PubMed  Google Scholar 

  14. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML (2013) GAPSS: the global anti-phospholipid syndrome score. Rheumatology (Oxford) 52:1397–1403. https://doi.org/10.1093/rheumatology/kes388

    Article  Google Scholar 

  15. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML (2015) The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxford) 54:134–138. https://doi.org/10.1093/rheumatology/keu307

    Article  CAS  Google Scholar 

  16. Oku K, Amengual O, Bohgaki T, Horita T, Yasuda S, Atsumi T (2015) An independent validation of the global anti-phospholipid syndrome score in a Japanese cohort of patients with autoimmune diseases. Lupus 24:774–775. https://doi.org/10.1177/0961203314561284

    Article  CAS  PubMed  Google Scholar 

  17. Fernandez Mosteirin N, Saez Comet L, Salvador Osuna C, Calvo Villas JM, Velilla Marco J (2017) Independent validation of the adjusted GAPSS: role of thrombotic risk assessment in the real-life setting. Lupus 26:1328–1332. https://doi.org/10.1177/0961203317703493

    Article  CAS  PubMed  Google Scholar 

  18. Radin M, Ugolini-Lopes MR, Sciascia S, Andrade D (2018) Extra-criteria manifestations of antiphospholipid syndrome: risk assessment and management. Semin Arthritis Rheum 48(1):117–120. https://doi.org/10.1016/j.semarthrit.2017.12.006

    Article  PubMed  Google Scholar 

  19. Kwaan HC, Samama M (2019) Clinical thrombosis. CRC Press

  20. Karande GY, Hedgire SS, Sanchez Y (2017) Advanced imaging in acute and chronic deep vein thrombosis. Cardiovasc Diagn Ther 6(6):493–507. https://doi.org/10.21037/cdt.2016.12.06

    Article  Google Scholar 

  21. Williams B, Mancia G, Spiering W, ESC Scientific Document Group et al (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39(33):3021–3104. https://doi.org/10.1093/eurheartj/ehy339

    Article  PubMed  Google Scholar 

  22. Grundy SM, Stone NJ, Bailey AL et al (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 73(24):3168–3209. https://doi.org/10.1016/j.jacc.2018.11.002

    Article  PubMed  Google Scholar 

  23. American Diabetes Association (2020) 2. Classification and diagnosis of diabetes: standards of medical Care in Diabetes-2020. Diabetes Care 43(Suppl 1):S14–S31. https://doi.org/10.2337/dc20-S002

    Article  Google Scholar 

  24. Pengo V (2012) ISTH guidelines on lupus anticoagulant testing. Thromb Res 130(Suppl 1):S76–S77. https://doi.org/10.1016/j.thromres.2012.08.283

    Article  PubMed  Google Scholar 

  25. Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF (2008) Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J 50(3):419–430. https://doi.org/10.1002/bimj.200710415

    Article  PubMed  PubMed Central  Google Scholar 

  26. Habibzadeh F, Habibzadeh P, Yadollahie M (2016) On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem Med (Zagreb) 26(3):297–307. https://doi.org/10.11613/BM.2016.034

    Article  Google Scholar 

  27. Ruffatti A, Del Ross T, Ciprian M et al (2009) Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis 68:397–399. https://doi.org/10.1136/ard.2008.096669

    Article  CAS  PubMed  Google Scholar 

  28. Sciascia S, Cosseddu D, Montaruli B, Kuzenko A, Bertero MT (2011) Risk scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis 70:1517–1518. https://doi.org/10.1136/ard.2010.145177

    Article  PubMed  Google Scholar 

  29. Sciascia S, Cuadrado MJ, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML (2014) Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. Arthritis Care Res 66(12):1915–1920. https://doi.org/10.1002/acr.22388

    Article  Google Scholar 

  30. Zuily S, de Laat B, Mohamed S, TAC(I)T investigators et al (2015) Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford) 54(11):2071–2075. https://doi.org/10.1093/rheumatology/kev238

    Article  CAS  Google Scholar 

  31. Sciascia S, Radin M, Sanna G, Cecchi I, Roccatello D, Bertolaccini ML (2018) Clinical utility of the global anti-phospholipid syndrome score (GAPSS) for risk stratification: a pooled analysis. Rheumatology (Oxford) 57(4):661–665. https://doi.org/10.1093/rheumatology/kex466

    Article  CAS  Google Scholar 

  32. Radin M, Sciascia S, Erkan D, APS ACTION et al (2019) The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort. Semin Arthritis Rheum 49(3):464–468. https://doi.org/10.1016/j.semarthrit.2019.04.009

    Article  PubMed  PubMed Central  Google Scholar 

  33. Radin M, Schreiber K, Costanzo P, Cecchi I, Roccatello D, Baldovino S, Bazzan M, Cuadrado MJ, Sciascia S (2017) The adjusted global antiphospholipid syndrome score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. Int J Cardiol 240:72–77. https://doi.org/10.1016/j.ijcard.2017.02.155

    Article  CAS  PubMed  Google Scholar 

  34. Radin M, Schreiber K, Cecchi I, Roccatello D, Cuadrado MJ, Sciascia S (2018) The risk of ischaemic stroke in primary APS patients: a prospective study. Eur J Neurol 25(2):320–325. https://doi.org/10.1111/ene.13499

    Article  CAS  PubMed  Google Scholar 

  35. Bettiol A, Emmi G, Finocchi M et al (2020) Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keaa116

  36. Veerasamy M, Bagnall A, Neely D, Allen J, Sinclair H, Kunadian V (2015) Endothelial dysfunction and coronary artery disease: a state of the art review. Cardiol Rev 23(3):119–129. https://doi.org/10.1097/CRD.0000000000000047

    Article  PubMed  Google Scholar 

  37. Libby P, Pasterkamp G, Crea F, Jang IK (2019) Reassessing the mechanisms of acute coronary syndromes. Circ Res 124(1):150–160. https://doi.org/10.1161/CIRCRESAHA.118.311098

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Mineo C (2013) Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis. Curr Rheumatol Rep 15(5):324. https://doi.org/10.1007/s11926-013-0324-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Jara LJ, Medina G, Vera-Lastra O, Amigo MC (2006) Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev 5(3):195–201. https://doi.org/10.1016/j.autrev.2005.06.005

    Article  PubMed  Google Scholar 

  40. Hollan I, Meroni PL, Ahearn JM et al (2013) Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 12(10):1004–1015. https://doi.org/10.1016/j.autrev.2013.03.013

    Article  CAS  PubMed  Google Scholar 

  41. Bilora F, Boccioletti V, Girolami B, Zanon E, Armani M, Petrobelli F, Girolami A (2002) Are antiphospholipid antibodies an independent risk factor for atherosclerosis? Clin Appl Thromb Hemost 8(2):103–113. https://doi.org/10.1177/107602960200800205

    Article  PubMed  Google Scholar 

  42. Matsuura E, Hughes GR, Khamashta MA (2008) Oxidation of LDL and its clinical implication. Autoimmun Rev 7(7):558–566. https://doi.org/10.1016/j.autrev.2008.04.018

    Article  CAS  PubMed  Google Scholar 

  43. Matsuura E, Kobayashi K, Inoue K, Lopez LR, Shoenfeld Y (2005) Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus 14(9):736–741. https://doi.org/10.1191/0961203305lu2211oa

    Article  CAS  PubMed  Google Scholar 

  44. Andrade D, Bortolotto L, Bonfá E, Borba E (2016) Primary antiphospholipid syndrome: absence of premature atherosclerosis in patients without traditional coronary artery disease risk factors. Lupus 25(5):472–478. https://doi.org/10.1177/0961203315617841

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

No funding to declare.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Capa, Fatih, 34093, Istanbul, Turkey

    Ömer Uludağ, Murat Bektaş, Yasemin Şahinkaya, Ahmet Gül, Murat Inanç, Lale Öcal & Bahar Artim-Esen

  2. Department of Statistics, Faculty of Arts and Science, Yıldız Technical University, Istanbul, Turkey

    Erhan Çene

  3. Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Murat Sezer

Authors
  1. Ömer Uludağ
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Murat Bektaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erhan Çene
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Murat Sezer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasemin Şahinkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ahmet Gül
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Murat Inanç
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lale Öcal
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bahar Artim-Esen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ömer Uludağ.

Ethics declarations

Conflict of interest

The authors do not have any conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uludağ, Ö., Bektaş, M., Çene, E. et al. Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey. J Thromb Thrombolysis 51, 466–474 (2021). https://doi.org/10.1007/s11239-020-02195-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-020-02195-4

Keywords

Search

Navigation